BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10873090)

  • 1. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia.
    Woodman AC; Goodison S; Drake M; Noble J; Tarin D
    Clin Cancer Res; 2000 Jun; 6(6):2381-92. PubMed ID: 10873090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
    Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
    J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
    Eissa S; Zohny SF; Swellam M; Mahmoud MH; El-Zayat TM; Salem AM
    Clin Biochem; 2008 Nov; 41(16-17):1335-41. PubMed ID: 18804101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma.
    Kageyama S; Isono T; Matsuda S; Ushio Y; Satomura S; Terai A; Arai Y; Kawakita M; Okada Y; Yoshiki T
    Int J Urol; 2009 May; 16(5):481-6. PubMed ID: 19389084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semiquantitative Detection of Abnormal CD44 Transcripts in Colon Carcinomas by Reverse Transcription-Polymerase Chain Reaction Enzyme-linked Immunosorbant Assay (RT-PCR ELISA).
    Yoshida K; Goodison S; Sugino T; Bolodeoku J; Churchman M; Warren BF; Tarin D
    Mol Diagn; 1996 Sep; 1(3):167-173. PubMed ID: 10462557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA breaks as measured by the alkaline comet assay in exfoliated cells as compared to voided urine cytology in the diagnosis of bladder cancer: a study of 105 subjects.
    Fracasso ME; Franceschetti P; Doria D; Talamini G; Bonetti F
    Mutat Res; 2004 Nov; 564(1):57-64. PubMed ID: 15474411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
    Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
    BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot.
    Eissa S; Swellam M; Labib RA; El-Zayat T; El Ahmady O
    J Urol; 2009 Mar; 181(3):1353-60. PubMed ID: 19185322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer.
    Attallah AM; Sakr HA; Ismail H; Abdel-Hady el-SK; El-Dosoky I
    BJU Int; 2005 Aug; 96(3):334-9. PubMed ID: 16042726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer.
    Bonner RB; Liebert M; Hurst RE; Grossman HB; Bane BL; Hemstreet GP
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):971-8. PubMed ID: 8959319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
    Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
    Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products.
    McCabe RP; Lamm DL; Haspel MV; Pomato N; Smith KO; Thompson E; Hanna MG
    Cancer Res; 1984 Dec; 44(12 Pt 1):5886-93. PubMed ID: 6498846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.